X

Source Natural Foods and Herbal Supplements Ltd. Stock Analysis

Small Cap
Evaluated by 138 users | BSE: 531398 | NSE: |
Pharmaceuticals & Drugs
Inwinex Pharmaceuticals, incorporated in 1995, is engaged in the manufacture of pharmaceuticals. Earlier known as Inwinex Laboratories, it got its present name on March 2, 2007. The company has been incurring losses for past couple of years on account of partial shutdown of the factory for...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed -18.24%-31.79%-13.72%8.26%3.56%3.24%7.96%20.05%10.54%12.6%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 0.40.51.63.84.56.510.915.910.812.8
Y-o-Y Gr. Rt.-28.6%244.4%141.9%21.1%44.1%67.1%45.8%-32%18.2%
Adjusted EPS (Rs.) -1.63-2.89-1.190.80.330.260.662.181.241.59
Y-o-Y Gr. Rt.-NANANA-58.8%-21.2%153.9%230.3%-43.1%28.2%
Book Value per Share (Rs.) 8.575.844.485.356.687.718.6410.8212.0713.66
Adjusted Net Profit -0.7-1.3-0.50.40.20.20.41.40.81
Net Op. Cash Flow (Rs. Cr.) -0.7-0.8-0.40.50.20.40.4-0.70.12.6
Debt to Cash Flow from Ops -0.72-1.27-5.084.5200.240.2-2.7516.40.06
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Source Natural Foods and Herbal Supplements Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 49.2%23.1%5.4%18.2%
Adjusted EPS NA37%34.1%28.2%
Book Value per Share 5.315.416.513.2
Share Price 20.5% 45.9% -0.8% 187.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) -31.55-38.78-22.4516.114.623.167.9822.4410.8712.4
Operating Profit Margin (%) -175.26-248.14-15.9615.038.5110.868.8411.4813.0312.39
Net Profit Margin (%) -212.12-287.73-34.449.573.792.463.918.827.398.01
Debt to Equity 0.120.3810.9200.020.010.270.230.02
Working Capital Days 69048614069727767105242166
Cash Conversion Cycle 34720013323323058172132
Entity Percentage Holding
Promoters 74.37%
Non-Institutions 25.63%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Source Natural Foods's performance infers:

Source Natural Foods earnings have grown by 37%, whereas share price has appreciated 45.9% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Source Natural Foods share prices over the last 10 years. Here is what we found out:

Source Natural Foods share price has appreciated 14.2% annually over the past ten years.

Inwinex Pharmaceuticals, incorporated in 1995, is engaged in the manufacture of pharmaceuticals. Earlier known as Inwinex Laboratories, it got its present name on March 2, 2007.

The company has been incurring losses for past couple of years on account of partial shutdown of the factory for renovation and inadequate working capital facilities. The factory, located at Hyderabad in Andhra Pradesh, has been completely shut down since April 12, 2006 due to inadequacy of working capital.

In

Inwinex Pharmaceuticals, incorporated in 1995, is engaged in the manufacture of pharmaceuticals. Earlier known as Inwinex Laboratories, it got its present name on March 2, 2007.

The company has been incurring losses for past couple of years on account of partial shutdown of the factory for renovation and inadequate working capital facilities. The factory, located at Hyderabad in Andhra Pradesh, has been completely shut down since April 12, 2006 due to inadequacy of working capital.

In 2000, company decided to hive-off the bulk drug unit and diversify into software related activities by changing the main clause. And in 2001, the company has signed an agreement with CDSL, NSDL and Venture Capital and Corporate Investment for dematerialization.

Business areas of the company:

The company manufactures antibiotics, norfloxacin, pefloxacin, enrofloxacin and electrolyte supplements.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback